Form 4: Electromed Director Skarvan Acquires 3,000 Shares

Electromed, Inc. Director Kathleen Skarvan acquired 3,000 shares of common stock, which are restricted and vest in June 2026.

Summary

• Kathleen Skarvan, a Director of Electromed, Inc. (ELMD), acquired 3,000 shares of common stock.
• The transaction occurred on December 1, 2025.
• These shares were acquired at a price of $0, indicating a grant of restricted stock.
• The restricted stock is scheduled to vest on June 1, 2026, unless earlier accelerated or terminated.
• Following this transaction, Skarvan beneficially owns 35,622 shares of common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even if restricted, generally indicates confidence in the company's future and aligns insider interests with shareholders. The $0 price suggests a compensation grant, which is a positive for retention and motivation.

Positives

• A Director, Kathleen Skarvan, increased her beneficial ownership in Electromed, Inc. by 3,000 shares, aligning her interests with shareholders.
• The acquisition of restricted stock at a $0 price suggests a compensation or incentive grant, which can motivate long-term commitment from management.

Risks

• The 3,000 restricted shares are subject to vesting conditions until June 1, 2026, and could be forfeited if the conditions are not met or employment terminates.

Future Outlook

The vesting of 3,000 restricted shares on June 1, 2026, indicates a future date when these shares will become fully owned by the director, potentially increasing her long-term stake and aligning her interests with future company performance.

Industry Context

This Form 4 filing details an insider transaction, which is a routine event in publicly traded companies across all industries, including the medical device sector. It reflects a director's compensation structure and personal investment in the company, rather than broader industry trends or competitive dynamics.

Comparison to Industry Standards

• Insider stock grants, particularly restricted stock units (RSUs) with vesting schedules and a $0 acquisition price, are a standard component of executive and director compensation packages across various industries, including medical devices.
• This practice aligns director interests with long-term company performance, similar to compensation structures observed in comparable medical technology companies such as Medtronic (MDT) or ResMed (RMD).

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with long-term shareholder value due to increased beneficial ownership.
• Management/Employees: The grant of restricted stock serves as an incentive for the director, potentially motivating long-term commitment and performance.

Next Steps

• The 3,000 restricted shares are scheduled to vest on June 1, 2026, at which point they will become fully owned by the director.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction where a director received restricted stock as part of compensation. While it shows alignment of interests, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard compensation event, not a signal for significant price movement or a re-evaluation of the company's intrinsic value.

Keywords

Electromed, ELMD, Kathleen Skarvan, Insider Transaction, Form 4, Stock Acquisition, Restricted Stock, Director, Beneficial Ownership